Malignant hyperthermia (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Malignant hyperthermia" in English language version.

refsWebsite

Global rank English rank

49nih.gov

4^th place

40doi.org

2^nd place

14semanticscholar.org

11^th place

8^th place

7web.archive.org

1^st place

3harvard.edu

18^th place

17^th place

1medlineplus.gov

1,581^st place

1,299^th place

1orpha.net

3,537^th place

7,177^th place

1zenodo.org

621^st place

380^th place

1worldcat.org

5^th place

1elsevier.com

610^th place

704^th place

1omim.org

4,380^th place

4,305^th place

1biophysj.org

low place

1umd.edu

1,747^th place

1,277^th place

1ivis.org

low place

1handle.net

102^nd place

76^th place

1asaabstracts.com

low place

1mhaus.org

low place

1mh.org.au

low place

1anesthesiology.org

low place

1merckvetmanual.com

9,011^th place

6,167^th place

anesthesiology.org

Denborough MA, Forster JF, Lovell RR, Maplestone PA, Villiers JD (1962). "Anaesthetic deaths in a family". British Journal of Anaesthesia. 34 (6): 395–6. doi:10.1093/bja/34.6.395. PMID 13885389. Historical account in Denborough MA (2008). "Malignant hyperthermia. 1962". Anesthesiology. 108 (1): 156–7. doi:10.1097/01.anes.0000296107.23210.dd. PMID 18156894.

asaabstracts.com

Stoker, Robert; Romankowski, Mathew; Burk, Kyle; Orr, Joseph (October 15, 2013). "12 Hour Evaluation of Filters to Prepare an Anesthesia Machine for Malignant Hyperthermia Susceptible Patients" (Abstract A4094). Anesthesiology 2013 Annual Meeting.

biophysj.org

Balog, E; Fruen, B; Shomer, N; Louis, C (2001). "Divergent effects of the malignant hyperthermia-susceptible Arg(615)-->Cys mutation on the Ca(2+) and Mg(2+) dependence of the RyR1". Biophys J. 81 (4): 2050–8. Bibcode:2001BpJ....81.2050B. doi:10.1016/S0006-3495(01)75854-7. PMC 1301678. PMID 11566777. Archived from the original on 2008-12-02.

doi.org

Schneiderbanger, D; Johannsen, S; Roewer, N; Schuster, F (2014). "Management of malignant hyperthermia: diagnosis and treatment". Therapeutics and Clinical Risk Management. 10: 355–62. doi:10.2147/TCRM.S47632. PMC 4027921. PMID 24868161.
Rosenberg H, Davis M, James D, Pollock N, Stowell K (April 2007). "Malignant hyperthermia". Orphanet Journal of Rare Diseases. 2: 21. doi:10.1186/1750-1172-2-21. PMC 1867813. PMID 17456235.
Litman, Ronald; Flood, Christopher D.; Kaplan, Richard F.; Kim, Yung Ly; Tobin, Joseph R. (November 2008). "Postoperative Malignant Hyperthermia". Anesthesiology. 109 (5): 825–9. doi:10.1097/aln.0b013e31818958e5. PMID 18946294.
Groom, Linda; Muldoon, Sheila M.; Tang, Zhen Zhi; Brandom, Barbara W.; Bayarsaikhan, Munkhuu; Bina, Saiid; Lee, Hee-Suk; Qiu, Xing; Sambuughin, Nyamkhishig; Dirksen, Robert T. (November 2011). "Identical de novo Mutation in the Type 1 Ryanodine Receptor Gene Associated with Fatal, Stress-induced Malignant Hyperthermia in Two Unrelated Families". Anesthesiology. 115 (5): 938–45. doi:10.1097/aln.0b013e3182320068. PMC 3203251. PMID 21918424.
Wang, Hui J.; Lee, Chang Seok; Yee, Rachel Sue Zhen; Groom, Linda; Friedman, Inbar; Babcock, Lyle; Georgiou, Dimitra K.; Hong, Jin; Hanna, Amy D.; Recio, Joseph; Choi, Jong Min (2020-10-09). "Adaptive thermogenesis enhances the life-threatening response to heat in mice with an Ryr1 mutation". Nature Communications. 11 (1): 5099. Bibcode:2020NatCo..11.5099W. doi:10.1038/s41467-020-18865-z. ISSN 2041-1723. PMC 7547078. PMID 33037202.
Hopkins, P.M. (July 2000). "Malignant hyperthermia: advances in clinical management and diagnosis". British Journal of Anaesthesia. 85 (1): 118–128. doi:10.1093/bja/85.1.118.
Gillard EF, Otsu K, Fujii J, Khanna VK, de Leon S, Derdemezi J, Britt BA, Duff CL, Worton RG, MacLennan DH (November 1991). "A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia". Genomics. 11 (3): 751–5. doi:10.1016/0888-7543(91)90084-R. PMID 1774074.
Galli L, Orrico A, Lorenzini S, Censini S, Falciani M, Covacci A, Tegazzin V, Sorrentino V (August 2006). "Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia". Human Mutation. 27 (8): 830. doi:10.1002/humu.9442. PMID 16835904. S2CID 32541866.
Balog, E; Fruen, B; Shomer, N; Louis, C (2001). "Divergent effects of the malignant hyperthermia-susceptible Arg(615)-->Cys mutation on the Ca(2+) and Mg(2+) dependence of the RyR1". Biophys J. 81 (4): 2050–8. Bibcode:2001BpJ....81.2050B. doi:10.1016/S0006-3495(01)75854-7. PMC 1301678. PMID 11566777. Archived from the original on 2008-12-02.
Yang T, Ta TA, Pessah IN, Allen PD (July 2003). "Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling". The Journal of Biological Chemistry. 278 (28): 25722–30. doi:10.1074/jbc.M302165200. PMID 12732639.
Monnier N, Procaccio V, Stieglitz P, Lunardi J (June 1997). "Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle". American Journal of Human Genetics. 60 (6): 1316–25. doi:10.1086/515454. PMC 1716149. PMID 9199552.
The R1086C mutant has never been published, but has nevertheless been referenced multiple times in the literature, e.g. Jurkat-Rott K, McCarthy T, Lehmann-Horn F (January 2000). "Genetics and pathogenesis of malignant hyperthermia". Muscle & Nerve. 23 (1): 4–17. doi:10.1002/(SICI)1097-4598(200001)23:1<4::AID-MUS3>3.0.CO;2-D. PMID 10590402. S2CID 17516858.
Weiss RG, O'Connell KM, Flucher BE, Allen PD, Grabner M, Dirksen RT (October 2004). "Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling". American Journal of Physiology. Cell Physiology. 287 (4): C1094–102. doi:10.1152/ajpcell.00173.2004. PMID 15201141. S2CID 18219662.
Litman R, Rosenberg H; Rosenberg (2005). "Malignant hyperthermia: update on susceptibility testing". JAMA. 293 (23): 2918–24. doi:10.1001/jama.293.23.2918. PMID 15956637.
J Fujii; K Otsu; F Zorzato; S de Leon; VK Khanna; JE Weiler; PJ O'Brien; DH MacLennan (1991). "Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia". Science. 253 (5018): 448–451. Bibcode:1991Sci...253..448F. doi:10.1126/science.1862346. PMID 1862346.
Aleman M, Nieto JE, Magdesian KG (2009). "Malignant hyperthermia associated with ryanodine receptor 1 (C7360G) mutation in Quarter Horses". Journal of Veterinary Internal Medicine. 23 (2): 329–34. doi:10.1111/j.1939-1676.2009.0274.x. PMID 19220734.
Valberg SJ, Mickelson JR, Gallant EM, MacLeay JM, Lentz L, de la Corte F (July 1999). "Exertional rhabdomyolysis in quarter horses and thoroughbreds: one syndrome, multiple aetiologies". Equine Veterinary Journal. Supplement. 31 (30): 533–8. doi:10.1111/j.2042-3306.1999.tb05279.x. PMID 10659313.
Yang T, Riehl J, Esteve E, Matthaei KI, Goth S, Allen PD, Pessah IN, Lopez JR (December 2006). "Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse". Anesthesiology. 105 (6): 1164–75. doi:10.1097/00000542-200612000-00016. hdl:1885/19871. PMID 17122579. S2CID 25219587.
Allen GC, Larach MG, Kunselman AR (March 1998). "The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS". Anesthesiology. 88 (3): 579–88. doi:10.1097/00000542-199803000-00006. PMID 9523799.
Schuster F, Gardill A, Metterlein T, Kranke P, Roewer N, Anetseder M (September 2007). "A minimally invasive metabolic test with intramuscular injection of halothane 5 and 6 vol% to detect probands at risk for malignant hyperthermia". Anaesthesia. 62 (9): 882–7. doi:10.1111/j.1365-2044.2007.05173.x. PMID 17697213. S2CID 26200473.
Anetseder M, Hager M, Müller CR, Roewer N (May 2002). "Diagnosis of susceptibility to malignant hyperthermia by use of a metabolic test". Lancet. 359 (9317): 1579–80. doi:10.1016/S0140-6736(02)08506-9. PMID 12047971. S2CID 46160746.
Larach MG, Localio AR, Allen GC, et al. (1994). "A clinical grading scale to predict malignant hyperthermia susceptibility". Anesthesiology. 80 (4): 771–9. doi:10.1097/00000542-199404000-00008. PMID 8024130. S2CID 23180468.
Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F (April 2004). "Dantrolene--a review of its pharmacology, therapeutic use and new developments". Anaesthesia. 59 (4): 364–73. doi:10.1111/j.1365-2044.2004.03658.x. PMID 15023108. S2CID 18537509.
Carr AS, Lerman J, Cunliffe M, McLeod ME, Britt BA (April 1995). "Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy". Canadian Journal of Anesthesia. 42 (4): 281–6. doi:10.1007/BF03010703. PMID 7788824.
Halsall PJ, Hopkins PM; Hopkins (2003). "Malignant hyperthermia". Continuing Education in Anaesthesia, Critical Care & Pain. 3 (1): 5–9. doi:10.1093/bjacepd/mkg002.
Kim TW, Nemergut ME (January 2011). "Preparation of modern anesthesia workstations for malignant hyperthermia-susceptible patients: a review of past and present practice". Anesthesiology. 114 (1): 205–12. doi:10.1097/ALN.0b013e3181ee2cb7. PMID 21169802.
EYH Yeung, Munroe J; Munroe (2015). "Development of a malignant hyperthermia protocol". BMC Proceedings. 9 (Suppl1): A32. doi:10.1186/1753-6561-9-S1-A32. PMC 4306034.
Cain CL, Riess ML, Gettrust L, Novalija J (2014). "Malignant hyperthermia crisis: optimizing patient outcomes through simulation and interdisciplinary collaboration". AORN Journal. 99 (2): 301–8, quiz 309–11. doi:10.1016/j.aorn.2013.06.012. PMC 4276305. PMID 24472592.
Hirshey Dirksen SJ, Van Wicklin SA, Mashman DL, Neiderer P, Merritt DR (2013). "Developing effective drills in preparation for a malignant hyperthermia crisis". AORN Journal. 97 (3): 329–53. doi:10.1016/j.aorn.2012.12.009. PMID 23452698. S2CID 41817148.
Isaak RS, Stiegler MP (2015). "Review of crisis resource management (CRM) principles in the setting of intraoperative malignant hyperthermia". Journal of Anesthesia. 30 (2): 298–306. doi:10.1007/s00540-015-2115-8. PMID 26679497. S2CID 25751256.
Holzman RS, Cooper JB, Gaba DM, Philip JH, Small SD, Feinstein D (1995). "Anesthesia crisis resource management: real-life simulation training in operating room crises". Journal of Clinical Anesthesia. 7 (8): 675–87. doi:10.1016/0952-8180(95)00146-8. PMID 8747567.
Rosenberg, Henry; Pollock, Neil; Schiemann, Anja; Bulger, Terasa; Stowell, Kathryn (4 August 2015). "Malignant hyperthermia: a review". Orphanet Journal of Rare Diseases. 10 (1): 93. doi:10.1186/s13023-015-0310-1. PMC 4524368. PMID 26238698.
Denborough MA, Forster JF, Lovell RR, Maplestone PA, Villiers JD (1962). "Anaesthetic deaths in a family". British Journal of Anaesthesia. 34 (6): 395–6. doi:10.1093/bja/34.6.395. PMID 13885389. Historical account in Denborough MA (2008). "Malignant hyperthermia. 1962". Anesthesiology. 108 (1): 156–7. doi:10.1097/01.anes.0000296107.23210.dd. PMID 18156894.
Hall LW, Woolf N, Bradley JW, Jolly DW (November 1966). "Unusual reaction to suxamethonium chloride". British Medical Journal. 2 (5525): 1305. doi:10.1136/bmj.2.5525.1305. PMC 1944316. PMID 5924819.
Harrison GG (January 1975). "Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium". British Journal of Anaesthesia. 47 (1): 62–5. doi:10.1093/bja/47.1.62. PMID 1148076. S2CID 21991166. A reprint of the article, which became a "Citation Classic", is available in Harrison GG (October 1998). "Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. 1975". Br J Anaesth. 81 (4): 626–9, discussion 625. doi:10.1093/bja/81.4.626. PMID 9924249.
Kolb ME, Horne ML, Martz R (April 1982). "Dantrolene in human malignant hyperthermia". Anesthesiology. 56 (4): 254–62. doi:10.1097/00000542-198204000-00005. PMID 7039419. S2CID 72069279.
Dexter F, Rosenberg H, Epstein RH, Semo JJ, Litman RS (2015). "Implications of National Anesthesia Workload on the Staffing of a Call Center: The Malignant Hyperthermia Consultant Hotline". A&A Case Reports. 5 (3): 43–6. doi:10.1213/XAA.0000000000000147. PMID 26230307.
Roberts, M. C.; Mickelson, J. R.; Patterson, E. E.; Nelson, T. E.; Armstrong, P. J.; Brunson, D. B.; Hogan, K (Sep 2001). "Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1)". Anesthesiology. 95 (3): 716–25. doi:10.1097/00000542-200109000-00026. PMID 11575546. S2CID 9999878.
Mickelson JR, Valberg SJ (2015). "The Genetics of Skeletal Muscle Disorders in Horses". Annu. Rev. Anim. Biosci. 3: 197–217. doi:10.1146/annurev-animal-022114-110653. PMID 25387114.
Dershwitz M, Sréter FA; Sréter (1990). "Azumolene reverses episodes of malignant hyperthermia in susceptible swine". Anesth. Analg. 70 (3): 253–5. doi:10.1213/00000539-199003000-00004. PMID 2305975. S2CID 10877298.

elsevier.com

linkinghub.elsevier.com

Hopkins, P.M. (July 2000). "Malignant hyperthermia: advances in clinical management and diagnosis". British Journal of Anaesthesia. 85 (1): 118–128. doi:10.1093/bja/85.1.118.

handle.net

hdl.handle.net

Yang T, Riehl J, Esteve E, Matthaei KI, Goth S, Allen PD, Pessah IN, Lopez JR (December 2006). "Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse". Anesthesiology. 105 (6): 1164–75. doi:10.1097/00000542-200612000-00016. hdl:1885/19871. PMID 17122579. S2CID 25219587.

harvard.edu

ui.adsabs.harvard.edu

Wang, Hui J.; Lee, Chang Seok; Yee, Rachel Sue Zhen; Groom, Linda; Friedman, Inbar; Babcock, Lyle; Georgiou, Dimitra K.; Hong, Jin; Hanna, Amy D.; Recio, Joseph; Choi, Jong Min (2020-10-09). "Adaptive thermogenesis enhances the life-threatening response to heat in mice with an Ryr1 mutation". Nature Communications. 11 (1): 5099. Bibcode:2020NatCo..11.5099W. doi:10.1038/s41467-020-18865-z. ISSN 2041-1723. PMC 7547078. PMID 33037202.
Balog, E; Fruen, B; Shomer, N; Louis, C (2001). "Divergent effects of the malignant hyperthermia-susceptible Arg(615)-->Cys mutation on the Ca(2+) and Mg(2+) dependence of the RyR1". Biophys J. 81 (4): 2050–8. Bibcode:2001BpJ....81.2050B. doi:10.1016/S0006-3495(01)75854-7. PMC 1301678. PMID 11566777. Archived from the original on 2008-12-02.
J Fujii; K Otsu; F Zorzato; S de Leon; VK Khanna; JE Weiler; PJ O'Brien; DH MacLennan (1991). "Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia". Science. 253 (5018): 448–451. Bibcode:1991Sci...253..448F. doi:10.1126/science.1862346. PMID 1862346.

ivis.org

Aleman, M.; Aldridge, B.M.; Riehl, J.; LeCouteur, R.A.; Stott, J.L.; Pesaah, I.N. (2004). "Equine Malignant Hyperthermia". ivis.org. Retrieved 3 March 2021.

medlineplus.gov

"malignant hyperthermia". Genetics Home Reference. Jan 27, 2017. Archived from the original on 27 June 2017. Retrieved 30 June 2017.

merckvetmanual.com

Lin, HuiChu (June 2018). "Malignant Hyperthermia in Dogs". Merck. Retrieved 24 January 2021.

mh.org.au

anaesthesia.mh.org.au

"Anaesthesia | the Royal Melbourne Hospital". Archived from the original on 2013-08-26. Retrieved 2014-03-17.

mhaus.org

Malignant Hyperthermia Association of the United States. "Preparing the Anesthesia Machine for MHS Patients". www.mhaus.org. Archived from the original on 2016-10-22. Retrieved 2017-06-22.

nih.gov

pubmed.ncbi.nlm.nih.gov

Schneiderbanger, D; Johannsen, S; Roewer, N; Schuster, F (2014). "Management of malignant hyperthermia: diagnosis and treatment". Therapeutics and Clinical Risk Management. 10: 355–62. doi:10.2147/TCRM.S47632. PMC 4027921. PMID 24868161.
Rosenberg H, Davis M, James D, Pollock N, Stowell K (April 2007). "Malignant hyperthermia". Orphanet Journal of Rare Diseases. 2: 21. doi:10.1186/1750-1172-2-21. PMC 1867813. PMID 17456235.
Litman, Ronald; Flood, Christopher D.; Kaplan, Richard F.; Kim, Yung Ly; Tobin, Joseph R. (November 2008). "Postoperative Malignant Hyperthermia". Anesthesiology. 109 (5): 825–9. doi:10.1097/aln.0b013e31818958e5. PMID 18946294.
Groom, Linda; Muldoon, Sheila M.; Tang, Zhen Zhi; Brandom, Barbara W.; Bayarsaikhan, Munkhuu; Bina, Saiid; Lee, Hee-Suk; Qiu, Xing; Sambuughin, Nyamkhishig; Dirksen, Robert T. (November 2011). "Identical de novo Mutation in the Type 1 Ryanodine Receptor Gene Associated with Fatal, Stress-induced Malignant Hyperthermia in Two Unrelated Families". Anesthesiology. 115 (5): 938–45. doi:10.1097/aln.0b013e3182320068. PMC 3203251. PMID 21918424.
Wang, Hui J.; Lee, Chang Seok; Yee, Rachel Sue Zhen; Groom, Linda; Friedman, Inbar; Babcock, Lyle; Georgiou, Dimitra K.; Hong, Jin; Hanna, Amy D.; Recio, Joseph; Choi, Jong Min (2020-10-09). "Adaptive thermogenesis enhances the life-threatening response to heat in mice with an Ryr1 mutation". Nature Communications. 11 (1): 5099. Bibcode:2020NatCo..11.5099W. doi:10.1038/s41467-020-18865-z. ISSN 2041-1723. PMC 7547078. PMID 33037202.
Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, Amemiya A, Rosenberg H, Sambuughin N, Riazi S, Dirksen R (2013). "Malignant Hyperthermia Susceptibility". GeneReviews. PMID 20301325.
Gillard EF, Otsu K, Fujii J, Khanna VK, de Leon S, Derdemezi J, Britt BA, Duff CL, Worton RG, MacLennan DH (November 1991). "A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia". Genomics. 11 (3): 751–5. doi:10.1016/0888-7543(91)90084-R. PMID 1774074.
Galli L, Orrico A, Lorenzini S, Censini S, Falciani M, Covacci A, Tegazzin V, Sorrentino V (August 2006). "Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia". Human Mutation. 27 (8): 830. doi:10.1002/humu.9442. PMID 16835904. S2CID 32541866.
Balog, E; Fruen, B; Shomer, N; Louis, C (2001). "Divergent effects of the malignant hyperthermia-susceptible Arg(615)-->Cys mutation on the Ca(2+) and Mg(2+) dependence of the RyR1". Biophys J. 81 (4): 2050–8. Bibcode:2001BpJ....81.2050B. doi:10.1016/S0006-3495(01)75854-7. PMC 1301678. PMID 11566777. Archived from the original on 2008-12-02.
Yang T, Ta TA, Pessah IN, Allen PD (July 2003). "Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling". The Journal of Biological Chemistry. 278 (28): 25722–30. doi:10.1074/jbc.M302165200. PMID 12732639.
Monnier N, Procaccio V, Stieglitz P, Lunardi J (June 1997). "Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle". American Journal of Human Genetics. 60 (6): 1316–25. doi:10.1086/515454. PMC 1716149. PMID 9199552.
The R1086C mutant has never been published, but has nevertheless been referenced multiple times in the literature, e.g. Jurkat-Rott K, McCarthy T, Lehmann-Horn F (January 2000). "Genetics and pathogenesis of malignant hyperthermia". Muscle & Nerve. 23 (1): 4–17. doi:10.1002/(SICI)1097-4598(200001)23:1<4::AID-MUS3>3.0.CO;2-D. PMID 10590402. S2CID 17516858.
Weiss RG, O'Connell KM, Flucher BE, Allen PD, Grabner M, Dirksen RT (October 2004). "Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling". American Journal of Physiology. Cell Physiology. 287 (4): C1094–102. doi:10.1152/ajpcell.00173.2004. PMID 15201141. S2CID 18219662.
Litman R, Rosenberg H; Rosenberg (2005). "Malignant hyperthermia: update on susceptibility testing". JAMA. 293 (23): 2918–24. doi:10.1001/jama.293.23.2918. PMID 15956637.
J Fujii; K Otsu; F Zorzato; S de Leon; VK Khanna; JE Weiler; PJ O'Brien; DH MacLennan (1991). "Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia". Science. 253 (5018): 448–451. Bibcode:1991Sci...253..448F. doi:10.1126/science.1862346. PMID 1862346.
Aleman M, Nieto JE, Magdesian KG (2009). "Malignant hyperthermia associated with ryanodine receptor 1 (C7360G) mutation in Quarter Horses". Journal of Veterinary Internal Medicine. 23 (2): 329–34. doi:10.1111/j.1939-1676.2009.0274.x. PMID 19220734.
Valberg SJ, Mickelson JR, Gallant EM, MacLeay JM, Lentz L, de la Corte F (July 1999). "Exertional rhabdomyolysis in quarter horses and thoroughbreds: one syndrome, multiple aetiologies". Equine Veterinary Journal. Supplement. 31 (30): 533–8. doi:10.1111/j.2042-3306.1999.tb05279.x. PMID 10659313.
Yang T, Riehl J, Esteve E, Matthaei KI, Goth S, Allen PD, Pessah IN, Lopez JR (December 2006). "Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse". Anesthesiology. 105 (6): 1164–75. doi:10.1097/00000542-200612000-00016. hdl:1885/19871. PMID 17122579. S2CID 25219587.
Allen GC, Larach MG, Kunselman AR (March 1998). "The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS". Anesthesiology. 88 (3): 579–88. doi:10.1097/00000542-199803000-00006. PMID 9523799.
Schuster F, Gardill A, Metterlein T, Kranke P, Roewer N, Anetseder M (September 2007). "A minimally invasive metabolic test with intramuscular injection of halothane 5 and 6 vol% to detect probands at risk for malignant hyperthermia". Anaesthesia. 62 (9): 882–7. doi:10.1111/j.1365-2044.2007.05173.x. PMID 17697213. S2CID 26200473.
Anetseder M, Hager M, Müller CR, Roewer N (May 2002). "Diagnosis of susceptibility to malignant hyperthermia by use of a metabolic test". Lancet. 359 (9317): 1579–80. doi:10.1016/S0140-6736(02)08506-9. PMID 12047971. S2CID 46160746.
Larach MG, Localio AR, Allen GC, et al. (1994). "A clinical grading scale to predict malignant hyperthermia susceptibility". Anesthesiology. 80 (4): 771–9. doi:10.1097/00000542-199404000-00008. PMID 8024130. S2CID 23180468.
Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F (April 2004). "Dantrolene--a review of its pharmacology, therapeutic use and new developments". Anaesthesia. 59 (4): 364–73. doi:10.1111/j.1365-2044.2004.03658.x. PMID 15023108. S2CID 18537509.
Carr AS, Lerman J, Cunliffe M, McLeod ME, Britt BA (April 1995). "Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy". Canadian Journal of Anesthesia. 42 (4): 281–6. doi:10.1007/BF03010703. PMID 7788824.
Kim TW, Nemergut ME (January 2011). "Preparation of modern anesthesia workstations for malignant hyperthermia-susceptible patients: a review of past and present practice". Anesthesiology. 114 (1): 205–12. doi:10.1097/ALN.0b013e3181ee2cb7. PMID 21169802.
Cain CL, Riess ML, Gettrust L, Novalija J (2014). "Malignant hyperthermia crisis: optimizing patient outcomes through simulation and interdisciplinary collaboration". AORN Journal. 99 (2): 301–8, quiz 309–11. doi:10.1016/j.aorn.2013.06.012. PMC 4276305. PMID 24472592.
Hirshey Dirksen SJ, Van Wicklin SA, Mashman DL, Neiderer P, Merritt DR (2013). "Developing effective drills in preparation for a malignant hyperthermia crisis". AORN Journal. 97 (3): 329–53. doi:10.1016/j.aorn.2012.12.009. PMID 23452698. S2CID 41817148.
Isaak RS, Stiegler MP (2015). "Review of crisis resource management (CRM) principles in the setting of intraoperative malignant hyperthermia". Journal of Anesthesia. 30 (2): 298–306. doi:10.1007/s00540-015-2115-8. PMID 26679497. S2CID 25751256.
Holzman RS, Cooper JB, Gaba DM, Philip JH, Small SD, Feinstein D (1995). "Anesthesia crisis resource management: real-life simulation training in operating room crises". Journal of Clinical Anesthesia. 7 (8): 675–87. doi:10.1016/0952-8180(95)00146-8. PMID 8747567.
Rosenberg, Henry; Pollock, Neil; Schiemann, Anja; Bulger, Terasa; Stowell, Kathryn (4 August 2015). "Malignant hyperthermia: a review". Orphanet Journal of Rare Diseases. 10 (1): 93. doi:10.1186/s13023-015-0310-1. PMC 4524368. PMID 26238698.
Denborough MA, Forster JF, Lovell RR, Maplestone PA, Villiers JD (1962). "Anaesthetic deaths in a family". British Journal of Anaesthesia. 34 (6): 395–6. doi:10.1093/bja/34.6.395. PMID 13885389. Historical account in Denborough MA (2008). "Malignant hyperthermia. 1962". Anesthesiology. 108 (1): 156–7. doi:10.1097/01.anes.0000296107.23210.dd. PMID 18156894.
Hall LW, Woolf N, Bradley JW, Jolly DW (November 1966). "Unusual reaction to suxamethonium chloride". British Medical Journal. 2 (5525): 1305. doi:10.1136/bmj.2.5525.1305. PMC 1944316. PMID 5924819.
Harrison GG (January 1975). "Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium". British Journal of Anaesthesia. 47 (1): 62–5. doi:10.1093/bja/47.1.62. PMID 1148076. S2CID 21991166. A reprint of the article, which became a "Citation Classic", is available in Harrison GG (October 1998). "Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. 1975". Br J Anaesth. 81 (4): 626–9, discussion 625. doi:10.1093/bja/81.4.626. PMID 9924249.
Kolb ME, Horne ML, Martz R (April 1982). "Dantrolene in human malignant hyperthermia". Anesthesiology. 56 (4): 254–62. doi:10.1097/00000542-198204000-00005. PMID 7039419. S2CID 72069279.
Dexter F, Rosenberg H, Epstein RH, Semo JJ, Litman RS (2015). "Implications of National Anesthesia Workload on the Staffing of a Call Center: The Malignant Hyperthermia Consultant Hotline". A&A Case Reports. 5 (3): 43–6. doi:10.1213/XAA.0000000000000147. PMID 26230307.
Roberts, M. C.; Mickelson, J. R.; Patterson, E. E.; Nelson, T. E.; Armstrong, P. J.; Brunson, D. B.; Hogan, K (Sep 2001). "Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1)". Anesthesiology. 95 (3): 716–25. doi:10.1097/00000542-200109000-00026. PMID 11575546. S2CID 9999878.
Mickelson JR, Valberg SJ (2015). "The Genetics of Skeletal Muscle Disorders in Horses". Annu. Rev. Anim. Biosci. 3: 197–217. doi:10.1146/annurev-animal-022114-110653. PMID 25387114.
Dershwitz M, Sréter FA; Sréter (1990). "Azumolene reverses episodes of malignant hyperthermia in susceptible swine". Anesth. Analg. 70 (3): 253–5. doi:10.1213/00000539-199003000-00004. PMID 2305975. S2CID 10877298.

ncbi.nlm.nih.gov

Schneiderbanger, D; Johannsen, S; Roewer, N; Schuster, F (2014). "Management of malignant hyperthermia: diagnosis and treatment". Therapeutics and Clinical Risk Management. 10: 355–62. doi:10.2147/TCRM.S47632. PMC 4027921. PMID 24868161.
Rosenberg H, Davis M, James D, Pollock N, Stowell K (April 2007). "Malignant hyperthermia". Orphanet Journal of Rare Diseases. 2: 21. doi:10.1186/1750-1172-2-21. PMC 1867813. PMID 17456235.
Groom, Linda; Muldoon, Sheila M.; Tang, Zhen Zhi; Brandom, Barbara W.; Bayarsaikhan, Munkhuu; Bina, Saiid; Lee, Hee-Suk; Qiu, Xing; Sambuughin, Nyamkhishig; Dirksen, Robert T. (November 2011). "Identical de novo Mutation in the Type 1 Ryanodine Receptor Gene Associated with Fatal, Stress-induced Malignant Hyperthermia in Two Unrelated Families". Anesthesiology. 115 (5): 938–45. doi:10.1097/aln.0b013e3182320068. PMC 3203251. PMID 21918424.
Wang, Hui J.; Lee, Chang Seok; Yee, Rachel Sue Zhen; Groom, Linda; Friedman, Inbar; Babcock, Lyle; Georgiou, Dimitra K.; Hong, Jin; Hanna, Amy D.; Recio, Joseph; Choi, Jong Min (2020-10-09). "Adaptive thermogenesis enhances the life-threatening response to heat in mice with an Ryr1 mutation". Nature Communications. 11 (1): 5099. Bibcode:2020NatCo..11.5099W. doi:10.1038/s41467-020-18865-z. ISSN 2041-1723. PMC 7547078. PMID 33037202.
Balog, E; Fruen, B; Shomer, N; Louis, C (2001). "Divergent effects of the malignant hyperthermia-susceptible Arg(615)-->Cys mutation on the Ca(2+) and Mg(2+) dependence of the RyR1". Biophys J. 81 (4): 2050–8. Bibcode:2001BpJ....81.2050B. doi:10.1016/S0006-3495(01)75854-7. PMC 1301678. PMID 11566777. Archived from the original on 2008-12-02.
Monnier N, Procaccio V, Stieglitz P, Lunardi J (June 1997). "Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle". American Journal of Human Genetics. 60 (6): 1316–25. doi:10.1086/515454. PMC 1716149. PMID 9199552.
EYH Yeung, Munroe J; Munroe (2015). "Development of a malignant hyperthermia protocol". BMC Proceedings. 9 (Suppl1): A32. doi:10.1186/1753-6561-9-S1-A32. PMC 4306034.
Cain CL, Riess ML, Gettrust L, Novalija J (2014). "Malignant hyperthermia crisis: optimizing patient outcomes through simulation and interdisciplinary collaboration". AORN Journal. 99 (2): 301–8, quiz 309–11. doi:10.1016/j.aorn.2013.06.012. PMC 4276305. PMID 24472592.
Rosenberg, Henry; Pollock, Neil; Schiemann, Anja; Bulger, Terasa; Stowell, Kathryn (4 August 2015). "Malignant hyperthermia: a review". Orphanet Journal of Rare Diseases. 10 (1): 93. doi:10.1186/s13023-015-0310-1. PMC 4524368. PMID 26238698.
Hall LW, Woolf N, Bradley JW, Jolly DW (November 1966). "Unusual reaction to suxamethonium chloride". British Medical Journal. 2 (5525): 1305. doi:10.1136/bmj.2.5525.1305. PMC 1944316. PMID 5924819.

rarediseases.info.nih.gov

"Malignant hyperthermia". GARD. 30 June 2014. Archived from the original on 4 July 2017. Retrieved 30 June 2017.

omim.org

"OMIM Entry - * 180901 - RYANODINE RECEPTOR 1; RYR1". www.omim.org. Retrieved 2016-01-06.

orpha.net

"Malignant hyperthermia" (PDF). Orpha.net. March 2013. Archived (PDF) from the original on 17 June 2013. Retrieved 30 June 2017.

semanticscholar.org

api.semanticscholar.org

Galli L, Orrico A, Lorenzini S, Censini S, Falciani M, Covacci A, Tegazzin V, Sorrentino V (August 2006). "Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia". Human Mutation. 27 (8): 830. doi:10.1002/humu.9442. PMID 16835904. S2CID 32541866.
The R1086C mutant has never been published, but has nevertheless been referenced multiple times in the literature, e.g. Jurkat-Rott K, McCarthy T, Lehmann-Horn F (January 2000). "Genetics and pathogenesis of malignant hyperthermia". Muscle & Nerve. 23 (1): 4–17. doi:10.1002/(SICI)1097-4598(200001)23:1<4::AID-MUS3>3.0.CO;2-D. PMID 10590402. S2CID 17516858.
Weiss RG, O'Connell KM, Flucher BE, Allen PD, Grabner M, Dirksen RT (October 2004). "Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling". American Journal of Physiology. Cell Physiology. 287 (4): C1094–102. doi:10.1152/ajpcell.00173.2004. PMID 15201141. S2CID 18219662.
Yang T, Riehl J, Esteve E, Matthaei KI, Goth S, Allen PD, Pessah IN, Lopez JR (December 2006). "Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse". Anesthesiology. 105 (6): 1164–75. doi:10.1097/00000542-200612000-00016. hdl:1885/19871. PMID 17122579. S2CID 25219587.
Schuster F, Gardill A, Metterlein T, Kranke P, Roewer N, Anetseder M (September 2007). "A minimally invasive metabolic test with intramuscular injection of halothane 5 and 6 vol% to detect probands at risk for malignant hyperthermia". Anaesthesia. 62 (9): 882–7. doi:10.1111/j.1365-2044.2007.05173.x. PMID 17697213. S2CID 26200473.
Anetseder M, Hager M, Müller CR, Roewer N (May 2002). "Diagnosis of susceptibility to malignant hyperthermia by use of a metabolic test". Lancet. 359 (9317): 1579–80. doi:10.1016/S0140-6736(02)08506-9. PMID 12047971. S2CID 46160746.
Larach MG, Localio AR, Allen GC, et al. (1994). "A clinical grading scale to predict malignant hyperthermia susceptibility". Anesthesiology. 80 (4): 771–9. doi:10.1097/00000542-199404000-00008. PMID 8024130. S2CID 23180468.
Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F (April 2004). "Dantrolene--a review of its pharmacology, therapeutic use and new developments". Anaesthesia. 59 (4): 364–73. doi:10.1111/j.1365-2044.2004.03658.x. PMID 15023108. S2CID 18537509.
Hirshey Dirksen SJ, Van Wicklin SA, Mashman DL, Neiderer P, Merritt DR (2013). "Developing effective drills in preparation for a malignant hyperthermia crisis". AORN Journal. 97 (3): 329–53. doi:10.1016/j.aorn.2012.12.009. PMID 23452698. S2CID 41817148.
Isaak RS, Stiegler MP (2015). "Review of crisis resource management (CRM) principles in the setting of intraoperative malignant hyperthermia". Journal of Anesthesia. 30 (2): 298–306. doi:10.1007/s00540-015-2115-8. PMID 26679497. S2CID 25751256.
Harrison GG (January 1975). "Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium". British Journal of Anaesthesia. 47 (1): 62–5. doi:10.1093/bja/47.1.62. PMID 1148076. S2CID 21991166. A reprint of the article, which became a "Citation Classic", is available in Harrison GG (October 1998). "Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. 1975". Br J Anaesth. 81 (4): 626–9, discussion 625. doi:10.1093/bja/81.4.626. PMID 9924249.
Kolb ME, Horne ML, Martz R (April 1982). "Dantrolene in human malignant hyperthermia". Anesthesiology. 56 (4): 254–62. doi:10.1097/00000542-198204000-00005. PMID 7039419. S2CID 72069279.
Roberts, M. C.; Mickelson, J. R.; Patterson, E. E.; Nelson, T. E.; Armstrong, P. J.; Brunson, D. B.; Hogan, K (Sep 2001). "Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1)". Anesthesiology. 95 (3): 716–25. doi:10.1097/00000542-200109000-00026. PMID 11575546. S2CID 9999878.
Dershwitz M, Sréter FA; Sréter (1990). "Azumolene reverses episodes of malignant hyperthermia in susceptible swine". Anesth. Analg. 70 (3): 253–5. doi:10.1213/00000539-199003000-00004. PMID 2305975. S2CID 10877298.

umd.edu

manc.umd.edu

Lenz, Tom R. "Heritable diseases of the American quarter horse and their management" (PDF). Archived from the original (PDF) on 2014-06-09. Retrieved 2012-06-12.

web.archive.org

"malignant hyperthermia". Genetics Home Reference. Jan 27, 2017. Archived from the original on 27 June 2017. Retrieved 30 June 2017.
"Malignant hyperthermia" (PDF). Orpha.net. March 2013. Archived (PDF) from the original on 17 June 2013. Retrieved 30 June 2017.
"Malignant hyperthermia". GARD. 30 June 2014. Archived from the original on 4 July 2017. Retrieved 30 June 2017.
Balog, E; Fruen, B; Shomer, N; Louis, C (2001). "Divergent effects of the malignant hyperthermia-susceptible Arg(615)-->Cys mutation on the Ca(2+) and Mg(2+) dependence of the RyR1". Biophys J. 81 (4): 2050–8. Bibcode:2001BpJ....81.2050B. doi:10.1016/S0006-3495(01)75854-7. PMC 1301678. PMID 11566777. Archived from the original on 2008-12-02.
Lenz, Tom R. "Heritable diseases of the American quarter horse and their management" (PDF). Archived from the original (PDF) on 2014-06-09. Retrieved 2012-06-12.
Malignant Hyperthermia Association of the United States. "Preparing the Anesthesia Machine for MHS Patients". www.mhaus.org. Archived from the original on 2016-10-22. Retrieved 2017-06-22.
"Anaesthesia | the Royal Melbourne Hospital". Archived from the original on 2013-08-26. Retrieved 2014-03-17.

worldcat.org

search.worldcat.org

Wang, Hui J.; Lee, Chang Seok; Yee, Rachel Sue Zhen; Groom, Linda; Friedman, Inbar; Babcock, Lyle; Georgiou, Dimitra K.; Hong, Jin; Hanna, Amy D.; Recio, Joseph; Choi, Jong Min (2020-10-09). "Adaptive thermogenesis enhances the life-threatening response to heat in mice with an Ryr1 mutation". Nature Communications. 11 (1): 5099. Bibcode:2020NatCo..11.5099W. doi:10.1038/s41467-020-18865-z. ISSN 2041-1723. PMC 7547078. PMID 33037202.

zenodo.org

Litman, Ronald; Flood, Christopher D.; Kaplan, Richard F.; Kim, Yung Ly; Tobin, Joseph R. (November 2008). "Postoperative Malignant Hyperthermia". Anesthesiology. 109 (5): 825–9. doi:10.1097/aln.0b013e31818958e5. PMID 18946294.